Kontratseptsiya: novye grani profilakticheskikh effektov


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the role of folic acid, which significantly reduces the risk of neural tube defects (NTDs) in the period of conception. Studies have shown that combined oral contraceptives (COCs) with folate significantly increase the levels of folate in the body. The main purpose of the new direction of contraception is prevention of fetal malformations that will be achieved by increase of folate levels in women of reproductive age against the background of contraception and after its abolition by receiving folate-containing contraceptives. Therefore, the amount of folate contained in the COC with folate reduces the risk of NTDs in the case of pregnancy during use of the drug or just after discontinuation of its use. Thus, currently, only taking contraceptives with folate, without other folate supplementation, a woman can receive a sufficient dose of folate for later conceiving a healthy child, making a contribution to the health of future children and protecting them from congenital defects associated with NTDs.

Full Text

Restricted Access

References

  1. Анализ данных об эффекте КОК на основе доказательной медицины из систематического обзора, Кокрановской библиотеки 20082011 гг.
  2. Bart St S, et al. Contraception 2012; 85:42-50.
  3. Botto LD, et al. N Engl J Med 1999;341 (20): 1509 19.
  4. Arya R, et al. J Neonatol 2006;20(4):316-26.
  5. Cheschier N. Int J Gynaecol Obstet 2003;83(1):123-33.
  6. de Jong-Van den Berg LT, et al. Am J Gynaecol Obstet 2005; 192(1):121-28.
  7. USPSTF. Ann Intern Med 2009;150(9):626-31.
  8. EUROCAT. Доступно на: http://www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIA.pdf.
  9. EUROCAT. Доступно на: http://www.eurocat-network.eu/content/Special-Report-NTD-3rdEd-Part-IIB.pdf.
  10. Lamers Y, et al. Am J Clin Nutr 2006;84(1): 156-61.
  11. De-Regil LM, et al. Cochrane Database Syst Rev 2010:CD007950.
  12. MMWR Morb Mortal Wkly Rep 2004;53(17):
  13. Busby A, et al. BMJ 2005;330(7491):574-5.
  14. Food & Drug Administration. Доступно на: http://www.fda.gov/ohrms/dockets/ac/03/ minutes/4002M 1_Final.pdf.
  15. Brown J. Nutrition through the life cycle (Third edition) 2008.
  16. Thomson Wadsworth: 109-110.
  17. Daly LE, et al. JAMA 1995;2 74:1698- 702.
  18. von Stenglin A, et al. Eur J Contracept Reprod Health Care 2010;15(s1):111-2 (реферат и стендовый доклад).
  19. Cronin M, et al. Obstet Gynecol 2009;114(3): 616-22.
  20. Diefenbach K, et al. Eur Contracept Reprod Health Care 2010;15(s1):111-2 (реферат и стендовый доклад).
  21. American Society for Reprodective Medicine, Denver, 2010.
  22. Osterhues A, et al. Lancet 2009;374(9694): 959-61.
  23. Ravin CR. AWHONN Lifelines 2004;8(1):12-3.
  24. de Jong-Van den Berg LT, et al. Am J Gynaecol Obstet 2005;192(1):121-28.
  25. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal model. Contraception 1995;51:99-110.
  26. Foidart JM, Oelkers W, Heithecker R. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: major breakthrough in tomorrow's oral contraception. Gynecol Snapshot 1995;3:13-7.
  27. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospire-none and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51.
  28. Rosenbaum P, Schmidt W, Helmerhorst FM, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000;5:16-24.
  29. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
  30. Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin Pharmacother 2007;8:989-99.
  31. Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000;5(Suppl. 3): 17-24.
  32. Fruzetti F, Lello S, Lazzarini V, et al. The oral contraceptive containing 30 mg of ethinylestradiol plus 3 mg drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 2007;75:199-223.
  33. Fruzzetti F, Lazzarini V, Ricci C, et al. Effect of an oral containing 30 mg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception 2007;76:190-94.
  34. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124-34.
  35. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34.
  36. Perry J, Chanarin I. Intestinal absorption of redusced folate compounds in man. Br J Haematol 1970;18:329-39.
  37. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-37.
  38. Czeizel AE, Duras I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-35.
  39. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-45.
  40. Botto LD, Moore CA,KhouryMJ, Erickson JD. Neuraltube defects. N Engl J Med 1999;341:1509-19.
  41. Wright JD, Bialostosky K, Gunter EW et al. Blood folate and vitamin B12: United States, 1988-1994. Vital Health Stat 1998; 11 (243): 1 - 78.
  42. Troen AM, Mitchell B, Sorensen B, et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 2006; 136:189-94.
  43. Beyaz®: an oral contraceptive fortified with folate Franca Fruzzetti Women's Health 2012;8( 1 ):13-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies